<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1994-06-01" modified="2017-12-20" version="204">
<accession>P35968</accession>
<accession>A2RRS0</accession>
<accession>B5A925</accession>
<accession>C5IFA0</accession>
<accession>O60723</accession>
<accession>Q14178</accession>
<name>VGFR2_HUMAN</name>
<protein>
<recommendedName>
<fullName>Vascular endothelial growth factor receptor 2</fullName>
<shortName>VEGFR-2</shortName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Fetal liver kinase 1</fullName>
<shortName>FLK-1</shortName>
</alternativeName>
<alternativeName>
<fullName>Kinase insert domain receptor</fullName>
<shortName>KDR</shortName>
</alternativeName>
<alternativeName>
<fullName>Protein-tyrosine kinase receptor flk-1</fullName>
</alternativeName>
<cdAntigenName>CD309</cdAntigenName>
</protein>
<gene>
<name type="primary">KDR</name>
<name type="synonym">FLK1</name>
<name type="synonym">VEGFR2</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="2008" name="Arthritis Res. Ther." volume="10" first="R73" last="R73">
<title>Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.</title>
<authorList>
<person name="Jin P."/>
<person name="Zhang J."/>
<person name="Sumariwalla P.F."/>
<person name="Ni I."/>
<person name="Jorgensen B."/>
<person name="Crawford D."/>
<person name="Phillips S."/>
<person name="Feldmann M."/>
<person name="Shepard H.M."/>
<person name="Paleolog E.M."/>
</authorList>
<dbReference type="PubMed" id="18593464"/>
<dbReference type="DOI" id="10.1186/ar2447"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
<scope>INTERACTION WITH VEGFC</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="2">
<citation type="journal article" date="2009" name="Nat. Med." volume="15" first="1023" last="1030">
<title>Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.</title>
<authorList>
<person name="Albuquerque R.J."/>
<person name="Hayashi T."/>
<person name="Cho W.G."/>
<person name="Kleinman M.E."/>
<person name="Dridi S."/>
<person name="Takeda A."/>
<person name="Baffi J.Z."/>
<person name="Yamada K."/>
<person name="Kaneko H."/>
<person name="Green M.G."/>
<person name="Chappell J."/>
<person name="Wilting J."/>
<person name="Weich H.A."/>
<person name="Yamagami S."/>
<person name="Amano S."/>
<person name="Mizuki N."/>
<person name="Alexander J.S."/>
<person name="Peterson M.L."/>
<person name="Brekken R.A."/>
<person name="Hirashima M."/>
<person name="Capoor S."/>
<person name="Usui T."/>
<person name="Ambati B.K."/>
<person name="Ambati J."/>
</authorList>
<dbReference type="PubMed" id="19668192"/>
<dbReference type="DOI" id="10.1038/nm.2018"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<scope>FUNCTION IN INHIBITION OF LYMPHANGIOGENESIS</scope>
<scope>INTERACTION WITH VEGFC</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="3">
<citation type="submission" date="1997-12" db="EMBL/GenBank/DDBJ databases">
<title>Full length human KDR/flk-1 sequence.</title>
<authorList>
<person name="Yin L.Y."/>
<person name="Wu Y."/>
<person name="Patterson C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
</reference>
<reference key="4">
<citation type="submission" date="1998-05" db="EMBL/GenBank/DDBJ databases">
<title>Coding region for human VEGF receptor KDR (VEGFR-2).</title>
<authorList>
<person name="Yu Y."/>
<person name="Whitney R.G."/>
<person name="Sato J.D."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<source>
<tissue>Umbilical vein</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="2005" name="Nature" volume="434" first="724" last="731">
<title>Generation and annotation of the DNA sequences of human chromosomes 2 and 4.</title>
<authorList>
<person name="Hillier L.W."/>
<person name="Graves T.A."/>
<person name="Fulton R.S."/>
<person name="Fulton L.A."/>
<person name="Pepin K.H."/>
<person name="Minx P."/>
<person name="Wagner-McPherson C."/>
<person name="Layman D."/>
<person name="Wylie K."/>
<person name="Sekhon M."/>
<person name="Becker M.C."/>
<person name="Fewell G.A."/>
<person name="Delehaunty K.D."/>
<person name="Miner T.L."/>
<person name="Nash W.E."/>
<person name="Kremitzki C."/>
<person name="Oddy L."/>
<person name="Du H."/>
<person name="Sun H."/>
<person name="Bradshaw-Cordum H."/>
<person name="Ali J."/>
<person name="Carter J."/>
<person name="Cordes M."/>
<person name="Harris A."/>
<person name="Isak A."/>
<person name="van Brunt A."/>
<person name="Nguyen C."/>
<person name="Du F."/>
<person name="Courtney L."/>
<person name="Kalicki J."/>
<person name="Ozersky P."/>
<person name="Abbott S."/>
<person name="Armstrong J."/>
<person name="Belter E.A."/>
<person name="Caruso L."/>
<person name="Cedroni M."/>
<person name="Cotton M."/>
<person name="Davidson T."/>
<person name="Desai A."/>
<person name="Elliott G."/>
<person name="Erb T."/>
<person name="Fronick C."/>
<person name="Gaige T."/>
<person name="Haakenson W."/>
<person name="Haglund K."/>
<person name="Holmes A."/>
<person name="Harkins R."/>
<person name="Kim K."/>
<person name="Kruchowski S.S."/>
<person name="Strong C.M."/>
<person name="Grewal N."/>
<person name="Goyea E."/>
<person name="Hou S."/>
<person name="Levy A."/>
<person name="Martinka S."/>
<person name="Mead K."/>
<person name="McLellan M.D."/>
<person name="Meyer R."/>
<person name="Randall-Maher J."/>
<person name="Tomlinson C."/>
<person name="Dauphin-Kohlberg S."/>
<person name="Kozlowicz-Reilly A."/>
<person name="Shah N."/>
<person name="Swearengen-Shahid S."/>
<person name="Snider J."/>
<person name="Strong J.T."/>
<person name="Thompson J."/>
<person name="Yoakum M."/>
<person name="Leonard S."/>
<person name="Pearman C."/>
<person name="Trani L."/>
<person name="Radionenko M."/>
<person name="Waligorski J.E."/>
<person name="Wang C."/>
<person name="Rock S.M."/>
<person name="Tin-Wollam A.-M."/>
<person name="Maupin R."/>
<person name="Latreille P."/>
<person name="Wendl M.C."/>
<person name="Yang S.-P."/>
<person name="Pohl C."/>
<person name="Wallis J.W."/>
<person name="Spieth J."/>
<person name="Bieri T.A."/>
<person name="Berkowicz N."/>
<person name="Nelson J.O."/>
<person name="Osborne J."/>
<person name="Ding L."/>
<person name="Meyer R."/>
<person name="Sabo A."/>
<person name="Shotland Y."/>
<person name="Sinha P."/>
<person name="Wohldmann P.E."/>
<person name="Cook L.L."/>
<person name="Hickenbotham M.T."/>
<person name="Eldred J."/>
<person name="Williams D."/>
<person name="Jones T.A."/>
<person name="She X."/>
<person name="Ciccarelli F.D."/>
<person name="Izaurralde E."/>
<person name="Taylor J."/>
<person name="Schmutz J."/>
<person name="Myers R.M."/>
<person name="Cox D.R."/>
<person name="Huang X."/>
<person name="McPherson J.D."/>
<person name="Mardis E.R."/>
<person name="Clifton S.W."/>
<person name="Warren W.C."/>
<person name="Chinwalla A.T."/>
<person name="Eddy S.R."/>
<person name="Marra M.A."/>
<person name="Ovcharenko I."/>
<person name="Furey T.S."/>
<person name="Miller W."/>
<person name="Eichler E.E."/>
<person name="Bork P."/>
<person name="Suyama M."/>
<person name="Torrents D."/>
<person name="Waterston R.H."/>
<person name="Wilson R.K."/>
</authorList>
<dbReference type="PubMed" id="15815621"/>
<dbReference type="DOI" id="10.1038/nature03466"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)</scope>
<scope>VARIANT HIS-472</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1991" name="Oncogene" volume="6" first="1677" last="1683">
<title>Identification of a new endothelial cell growth factor receptor tyrosine kinase.</title>
<authorList>
<person name="Terman B.I."/>
<person name="Carrion M.E."/>
<person name="Kovacs E."/>
<person name="Rasmussen B.A."/>
<person name="Eddy R.L."/>
<person name="Shows T.B."/>
</authorList>
<dbReference type="PubMed" id="1656371"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 3-1356 (ISOFORM 1)</scope>
<scope>VARIANT GLU-848</scope>
<source>
<tissue>Umbilical vein</tissue>
</source>
</reference>
<reference key="8">
<citation type="journal article" date="1995" name="J. Biol. Chem." volume="270" first="23111" last="23118">
<title>Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor.</title>
<authorList>
<person name="Patterson C."/>
<person name="Perrella M.A."/>
<person name="Hsieh C.-M."/>
<person name="Yoshizumi M."/>
<person name="Lee M.-E."/>
<person name="Harber E."/>
</authorList>
<dbReference type="PubMed" id="7559454"/>
<dbReference type="DOI" id="10.1074/jbc.270.39.23111"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1992" name="Biochem. Biophys. Res. Commun." volume="187" first="1579" last="1586">
<title>Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.</title>
<authorList>
<person name="Terman B.I."/>
<person name="Dougher-Vermazen M."/>
<person name="Carrion M.E."/>
<person name="Dimitrov D."/>
<person name="Armellino D.C."/>
<person name="Gospodarowicz D."/>
<person name="Boehlen P."/>
</authorList>
<dbReference type="PubMed" id="1417831"/>
<dbReference type="DOI" id="10.1016/0006-291X(92)90483-2"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH VEGFA</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="26988" last="26995">
<title>Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.</title>
<authorList>
<person name="Waltenberger J."/>
<person name="Claesson-Welsh L."/>
<person name="Siegbahn A."/>
<person name="Shibuya M."/>
<person name="Heldin C.H."/>
</authorList>
<dbReference type="PubMed" id="7929439"/>
</citation>
<scope>FUNCTION AS VEGFA RECEPTOR; IN REGULATION OF CELL SHAPE; ACTIN CYTOSKELETON REORGANIZATION; CELL MIGRATION AND CELL PROLIFERATION</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1997" name="Oncogene" volume="14" first="2079" last="2089">
<title>The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.</title>
<authorList>
<person name="Takahashi T."/>
<person name="Shibuya M."/>
</authorList>
<dbReference type="PubMed" id="9160888"/>
<dbReference type="DOI" id="10.1038/sj.onc.1201047"/>
</citation>
<scope>FUNCTION IN VEGFA SIGNALING; PHOSPHORYLATION OF PLCG1; ACTIVATION OF MAP KINASES AND IN PROMOTING PROLIFERATION OF ENDOTHELIAL CELLS</scope>
<scope>INTERACTION WITH VEGFA AND PLCG1</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>GLYCOSYLATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1998" name="Biochem. Biophys. Res. Commun." volume="252" first="743" last="746">
<title>VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR).</title>
<authorList>
<person name="Kroll J."/>
<person name="Waltenberger J."/>
</authorList>
<dbReference type="PubMed" id="9837777"/>
<dbReference type="DOI" id="10.1006/bbrc.1998.9719"/>
</citation>
<scope>FUNCTION IN INDUCTION OF NOS2 AND NOS3</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="30336" last="30343">
<title>Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.</title>
<authorList>
<person name="Gerber H.P."/>
<person name="McMurtrey A."/>
<person name="Kowalski J."/>
<person name="Yan M."/>
<person name="Keyt B.A."/>
<person name="Dixit V."/>
<person name="Ferrara N."/>
</authorList>
<dbReference type="PubMed" id="9804796"/>
<dbReference type="DOI" id="10.1074/jbc.273.46.30336"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1 SIGNALING PATHWAY</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1999" name="Biochem. Biophys. Res. Commun." volume="265" first="636" last="639">
<title>A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells.</title>
<authorList>
<person name="Kroll J."/>
<person name="Waltenberger J."/>
</authorList>
<dbReference type="PubMed" id="10600473"/>
<dbReference type="DOI" id="10.1006/bbrc.1999.1729"/>
</citation>
<scope>FUNCTION IN NITRIC OXIDE RELEASE</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1999" name="J. Biol. Chem." volume="274" first="6453" last="6460">
<title>Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues.</title>
<authorList>
<person name="Kendall R.L."/>
<person name="Rutledge R.Z."/>
<person name="Mao X."/>
<person name="Tebben A.J."/>
<person name="Hungate R.W."/>
<person name="Thomas K.A."/>
</authorList>
<dbReference type="PubMed" id="10037737"/>
<dbReference type="DOI" id="10.1074/jbc.274.10.6453"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>CHARACTERIZATION OF VARIANT GLU-848</scope>
<scope>PHOSPHORYLATION AT TYR-1054 AND TYR-1059</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1999" name="Oncogene" volume="18" first="1619" last="1627">
<title>Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization.</title>
<authorList>
<person name="Dougher M."/>
<person name="Terman B.I."/>
</authorList>
<dbReference type="PubMed" id="10102632"/>
<dbReference type="DOI" id="10.1038/sj.onc.1202478"/>
</citation>
<scope>FUNCTION IN PHOSPHORYLATION OF PLCG1 AND PTK2/FAK1</scope>
<scope>INTERACTION WITH VEGFA</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>PHOSPHORYLATION AT TYR-996; TYR-1054 AND TYR-1059</scope>
<scope>MUTAGENESIS OF TYR-996; TYR-1054 AND TYR-1059</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2000" name="J. Virol." volume="74" first="344" last="353">
<title>Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.</title>
<authorList>
<person name="Mitola S."/>
<person name="Soldi R."/>
<person name="Zanon I."/>
<person name="Barra L."/>
<person name="Gutierrez M.I."/>
<person name="Berkhout B."/>
<person name="Giacca M."/>
<person name="Bussolino F."/>
</authorList>
<dbReference type="PubMed" id="10590123"/>
<dbReference type="DOI" id="10.1128/JVI.74.1.344-353.2000"/>
</citation>
<scope>INTERACTION WITH HIV-1 TAT</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2001" name="EMBO J." volume="20" first="2768" last="2778">
<title>A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.</title>
<authorList>
<person name="Takahashi T."/>
<person name="Yamaguchi S."/>
<person name="Chida K."/>
<person name="Shibuya M."/>
</authorList>
<dbReference type="PubMed" id="11387210"/>
<dbReference type="DOI" id="10.1093/emboj/20.11.2768"/>
</citation>
<scope>FUNCTION IN ENDOTHELIAL CELL PROLIFERATION; PHOSPHORYLATION OF PLCG1 AND ACTIVATION OF MAP KINASES</scope>
<scope>PHOSPHORYLATION AT TYR-1175 AND TYR-1214</scope>
<scope>MUTAGENESIS OF LYS-868 AND TYR-1175</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="20091" last="20097">
<title>Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination. Consequences on nitric oxide production from endothelial cells.</title>
<authorList>
<person name="Duval M."/>
<person name="Bedard-Goulet S."/>
<person name="Delisle C."/>
<person name="Gratton J.P."/>
</authorList>
<dbReference type="PubMed" id="12649282"/>
<dbReference type="DOI" id="10.1074/jbc.M301410200"/>
</citation>
<scope>UBIQUITINATION</scope>
<scope>FUNCTION IN NITRIC OXIDE PRODUCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH CBL</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="40973" last="40979">
<title>Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites.</title>
<authorList>
<person name="Dixelius J."/>
<person name="Makinen T."/>
<person name="Wirzenius M."/>
<person name="Karkkainen M.J."/>
<person name="Wernstedt C."/>
<person name="Alitalo K."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="12881528"/>
<dbReference type="DOI" id="10.1074/jbc.M304499200"/>
</citation>
<scope>INTERACTION WITH FLT4</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="22267" last="22275">
<title>The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration.</title>
<authorList>
<person name="Holmqvist K."/>
<person name="Cross M.J."/>
<person name="Rolny C."/>
<person name="Haegerkvist R."/>
<person name="Rahimi N."/>
<person name="Matsumoto T."/>
<person name="Claesson-Welsh L."/>
<person name="Welsh M."/>
</authorList>
<dbReference type="PubMed" id="15026417"/>
<dbReference type="DOI" id="10.1074/jbc.M312729200"/>
</citation>
<scope>INTERACTION WITH SHB</scope>
<scope>FUNCTION IN CELL MIGRATION</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2004" name="J. Pathol." volume="202" first="313" last="320">
<title>Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus.</title>
<authorList>
<person name="Fox S.B."/>
<person name="Turley H."/>
<person name="Cheale M."/>
<person name="Blazquez C."/>
<person name="Roberts H."/>
<person name="James N."/>
<person name="Cook N."/>
<person name="Harris A."/>
<person name="Gatter K."/>
</authorList>
<dbReference type="PubMed" id="14991896"/>
<dbReference type="DOI" id="10.1002/path.1520"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="36148" last="36157">
<title>Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells.</title>
<authorList>
<person name="Jia H."/>
<person name="Bagherzadeh A."/>
<person name="Bicknell R."/>
<person name="Duchen M.R."/>
<person name="Liu D."/>
<person name="Zachary I."/>
</authorList>
<dbReference type="PubMed" id="15215251"/>
<dbReference type="DOI" id="10.1074/jbc.M401538200"/>
</citation>
<scope>INTERACTION WITH VEGFA AND VEGFD</scope>
<scope>PHOSPHORYLATION AT TYR-1054 AND TYR-1059</scope>
<scope>FUNCTION IN VEGFA AND VEGFD SIGNALING; ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1; ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3; MODULATION OF INTRACELLULAR CA(2+) LEVELS; CELL SURVIVAL AND POSITIVE REGULATION OF CELL PROLIFERATION; CELL MIGRATION AND ANGIOGENESIS</scope>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2005" name="EMBO J." volume="24" first="2342" last="2353">
<title>VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis.</title>
<authorList>
<person name="Matsumoto T."/>
<person name="Bohman S."/>
<person name="Dixelius J."/>
<person name="Berge T."/>
<person name="Dimberg A."/>
<person name="Magnusson P."/>
<person name="Wang L."/>
<person name="Wikner C."/>
<person name="Qi J.H."/>
<person name="Wernstedt C."/>
<person name="Wu J."/>
<person name="Bruheim S."/>
<person name="Mugishima H."/>
<person name="Mukhopadhyay D."/>
<person name="Spurkland A."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="15962004"/>
<dbReference type="DOI" id="10.1038/sj.emboj.7600709"/>
</citation>
<scope>FUNCTION IN CELL MIGRATION; PHOSPHORYLATION OF PLCG1; ACTIVATION OF MAPK1/ERK2; MAPK3/ERK1 AND THE MAP KINASES AND IN REGULATION OF ACTIN CYTOSKELETON REORGANIZATION</scope>
<scope>INTERACTION WITH SH2D2A/TSAD</scope>
<scope>PHOSPHORYLATION AT TYR-951; TYR-1054; TYR-1059; TYR-1214; TYR-1305; TYR-1309 AND TYR-1319</scope>
<scope>MUTAGENESIS OF TYR-951</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="34009" last="34020">
<title>Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF.</title>
<authorList>
<person name="Lamalice L."/>
<person name="Houle F."/>
<person name="Huot J."/>
</authorList>
<dbReference type="PubMed" id="16966330"/>
<dbReference type="DOI" id="10.1074/jbc.M603928200"/>
</citation>
<scope>FUNCTION IN ENDOTHELIAL CELL MIGRATION; ACTIVATION OF MAP KINASES AND IN PHOSPHORYLATION OF FYN; SRC AND NCK1</scope>
<scope>INTERACTION WITH GRB2; FYN AND NCK1</scope>
<scope>MUTAGENESIS OF TYR-1214</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2006" name="Traffic" volume="7" first="1270" last="1282">
<title>Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells.</title>
<authorList>
<person name="Ewan L.C."/>
<person name="Jopling H.M."/>
<person name="Jia H."/>
<person name="Mittar S."/>
<person name="Bagherzadeh A."/>
<person name="Howell G.J."/>
<person name="Walker J.H."/>
<person name="Zachary I.C."/>
<person name="Ponnambalam S."/>
</authorList>
<dbReference type="PubMed" id="17004325"/>
<dbReference type="DOI" id="10.1111/j.1600-0854.2006.00462.x"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>UBIQUITINATION</scope>
<scope>DEGRADATION</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="10660" last="10669">
<title>Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells.</title>
<authorList>
<person name="Blanes M.G."/>
<person name="Oubaha M."/>
<person name="Rautureau Y."/>
<person name="Gratton J.P."/>
</authorList>
<dbReference type="PubMed" id="17303569"/>
<dbReference type="DOI" id="10.1074/jbc.M609048200"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF AKT1; PHOSPHORYLATION OF PLCG1 AND NOS3 AND REGULATION OF NITRIC OXIDE PRODUCTION</scope>
<scope>PHOSPHORYLATION AT TYR-801</scope>
<scope>MUTAGENESIS OF TYR-801</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2008" name="J. Clin. Invest." volume="118" first="3904" last="3916">
<title>AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice.</title>
<authorList>
<person name="Zhang H."/>
<person name="He Y."/>
<person name="Dai S."/>
<person name="Xu Z."/>
<person name="Luo Y."/>
<person name="Wan T."/>
<person name="Luo D."/>
<person name="Jones D."/>
<person name="Tang S."/>
<person name="Chen H."/>
<person name="Sessa W.C."/>
<person name="Min W."/>
</authorList>
<dbReference type="PubMed" id="19033661"/>
<dbReference type="DOI" id="10.1172/JCI36168"/>
</citation>
<scope>INTERACTION WITH DAB2IP</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2009" name="FASEB J." volume="23" first="1490" last="1502">
<title>Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis.</title>
<authorList>
<person name="Mellberg S."/>
<person name="Dimberg A."/>
<person name="Bahram F."/>
<person name="Hayashi M."/>
<person name="Rennel E."/>
<person name="Ameur A."/>
<person name="Westholm J.O."/>
<person name="Larsson E."/>
<person name="Lindahl P."/>
<person name="Cross M.J."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="19136612"/>
<dbReference type="DOI" id="10.1096/fj.08-123810"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-951; TYR-1175 AND TYR-1214</scope>
<scope>DEPHOSPHORYLATION BY PTPRB</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2009" name="Mol. Cell. Biol." volume="29" first="241" last="253">
<title>New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival.</title>
<authorList>
<person name="Chabot C."/>
<person name="Spring K."/>
<person name="Gratton J.P."/>
<person name="Elchebly M."/>
<person name="Royal I."/>
</authorList>
<dbReference type="PubMed" id="18936167"/>
<dbReference type="DOI" id="10.1128/MCB.01374-08"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-801; TYR-951; TYR-996; TYR-1054; TYR-1059; TYR-1175 AND TYR-1214; DEPHOSPHORYLATION AT TYR-951; TYR-996; TYR-1054; TYR-1059; TYR-1175 AND TYR-1214 BY PTPRJ</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2010" name="Cell Death Differ." volume="17" first="499" last="512">
<title>VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.</title>
<authorList>
<person name="Zhang Z."/>
<person name="Neiva K.G."/>
<person name="Lingen M.W."/>
<person name="Ellis L.M."/>
<person name="Nor J.E."/>
</authorList>
<dbReference type="PubMed" id="19834490"/>
<dbReference type="DOI" id="10.1038/cdd.2009.152"/>
</citation>
<scope>FUNCTION AS VEGFA RECEPTOR IN TUMOR ANGIOGENESIS</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>UBIQUITINATION</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2010" name="Clin. Cancer Res." volume="16" first="1431" last="1441">
<title>Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.</title>
<authorList>
<person name="Becker J."/>
<person name="Pavlakovic H."/>
<person name="Ludewig F."/>
<person name="Wilting F."/>
<person name="Weich H.A."/>
<person name="Albuquerque R."/>
<person name="Ambati J."/>
<person name="Wilting J."/>
</authorList>
<dbReference type="PubMed" id="20179233"/>
<dbReference type="DOI" id="10.1158/1078-0432.CCR-09-1936"/>
</citation>
<scope>FUNCTION IN LYMPHANGIOGENESIS (ISOFORM 2)</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2010" name="EMBO J." volume="29" first="1377" last="1388">
<title>VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.</title>
<authorList>
<person name="Nilsson I."/>
<person name="Bahram F."/>
<person name="Li X."/>
<person name="Gualandi L."/>
<person name="Koch S."/>
<person name="Jarvius M."/>
<person name="Soderberg O."/>
<person name="Anisimov A."/>
<person name="Kholova I."/>
<person name="Pytowski B."/>
<person name="Baldwin M."/>
<person name="Yla-Herttuala S."/>
<person name="Alitalo K."/>
<person name="Kreuger J."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="20224550"/>
<dbReference type="DOI" id="10.1038/emboj.2010.30"/>
</citation>
<scope>INTERACTION WITH VEGFC AND FLT4</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>FUNCTION IN ANGIOGENESIS</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2011" name="Biochem. Biophys. Res. Commun." volume="410" first="170" last="176">
<title>The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling.</title>
<authorList>
<person name="Jopling H.M."/>
<person name="Howell G.J."/>
<person name="Gamper N."/>
<person name="Ponnambalam S."/>
</authorList>
<dbReference type="PubMed" id="21539813"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2011.04.093"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2011" name="Blood" volume="117" first="1081" last="1090">
<title>Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis.</title>
<authorList>
<person name="Nakao S."/>
<person name="Zandi S."/>
<person name="Hata Y."/>
<person name="Kawahara S."/>
<person name="Arita R."/>
<person name="Schering A."/>
<person name="Sun D."/>
<person name="Melhorn M.I."/>
<person name="Ito Y."/>
<person name="Lara-Castillo N."/>
<person name="Ishibashi T."/>
<person name="Hafezi-Moghadam A."/>
</authorList>
<dbReference type="PubMed" id="20705758"/>
<dbReference type="DOI" id="10.1182/blood-2010-02-267427"/>
</citation>
<scope>FUNCTION IN LYMPHANGIOGENESIS</scope>
<scope>INTERACTION WITH FLT4 AND VEGFC</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2006" name="J. Biochem. Mol. Biol." volume="39" first="469" last="478">
<title>Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.</title>
<authorList>
<person name="Shibuya M."/>
</authorList>
<dbReference type="PubMed" id="17002866"/>
<dbReference type="DOI" id="10.5483/BMBRep.2006.39.5.469"/>
</citation>
<scope>REVIEW ON ROLE IN ANGIOGENESIS</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2007" name="Cell. Signal." volume="19" first="2003" last="2012">
<title>Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.</title>
<authorList>
<person name="Holmes K."/>
<person name="Roberts O.L."/>
<person name="Thomas A.M."/>
<person name="Cross M.J."/>
</authorList>
<dbReference type="PubMed" id="17658244"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2007.05.013"/>
</citation>
<scope>REVIEW</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2008" name="Biochem. Biophys. Res. Commun." volume="375" first="287" last="291">
<title>VEGF receptor protein-tyrosine kinases: structure and regulation.</title>
<authorList>
<person name="Roskoski R. Jr."/>
</authorList>
<dbReference type="PubMed" id="18680722"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2008.07.121"/>
</citation>
<scope>REVIEW ON STRUCTURE AND FUNCTION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2009" name="Curr. Opin. Cell Biol." volume="21" first="154" last="165">
<title>VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.</title>
<authorList>
<person name="Lohela M."/>
<person name="Bry M."/>
<person name="Tammela T."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="19230644"/>
<dbReference type="DOI" id="10.1016/j.ceb.2008.12.012"/>
</citation>
<scope>REVIEW ON ROLE IN ANGIOGENESIS AND CANCER</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2010" name="Biochim. Biophys. Acta" volume="1804" first="567" last="580">
<title>Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling.</title>
<authorList>
<person name="Grunewald F.S."/>
<person name="Prota A.E."/>
<person name="Giese A."/>
<person name="Ballmer-Hofer K."/>
</authorList>
<dbReference type="PubMed" id="19761875"/>
<dbReference type="DOI" id="10.1016/j.bbapap.2009.09.002"/>
</citation>
<scope>REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND SIGNALING</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2010" name="Biochim. Biophys. Acta" volume="1806" first="108" last="121">
<title>Vascular endothelial growth factor receptor-2 in breast cancer.</title>
<authorList>
<person name="Guo S."/>
<person name="Colbert L.S."/>
<person name="Fuller M."/>
<person name="Zhang Y."/>
<person name="Gonzalez-Perez R.R."/>
</authorList>
<dbReference type="PubMed" id="20462514"/>
<dbReference type="DOI" id="10.1016/j.bbcan.2010.04.004"/>
</citation>
<scope>REVIEW ON ROLE IN ANGIOGENESIS AND CANCER</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2010" name="Genes Cancer" volume="1" first="1119" last="1123">
<title>Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer.</title>
<authorList>
<person name="Shibuya M."/>
</authorList>
<dbReference type="PubMed" id="21779435"/>
<dbReference type="DOI" id="10.1177/1947601910392987"/>
</citation>
<scope>REVIEW ON ROLE IN ANGIOGENESIS AND CANCER</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2011" name="Biochem. J." volume="437" first="169" last="183">
<title>Signal transduction by vascular endothelial growth factor receptors.</title>
<authorList>
<person name="Koch S."/>
<person name="Tugues S."/>
<person name="Li X."/>
<person name="Gualandi L."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="21711246"/>
<dbReference type="DOI" id="10.1042/BJ20110301"/>
</citation>
<scope>REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND SIGNALING</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2011" name="Sci. Signal." volume="4" first="RS3" last="RS3">
<title>System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.</title>
<authorList>
<person name="Rigbolt K.T."/>
<person name="Prokhorova T.A."/>
<person name="Akimov V."/>
<person name="Henningsen J."/>
<person name="Johansen P.T."/>
<person name="Kratchmarova I."/>
<person name="Kassem M."/>
<person name="Mann M."/>
<person name="Olsen J.V."/>
<person name="Blagoev B."/>
</authorList>
<dbReference type="PubMed" id="21406692"/>
<dbReference type="DOI" id="10.1126/scisignal.2001570"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-982 AND SER-984</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2012" name="Cell. Signal." volume="24" first="131" last="139">
<title>Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.</title>
<authorList>
<person name="Rho S.B."/>
<person name="Song Y.J."/>
<person name="Lim M.C."/>
<person name="Lee S.H."/>
<person name="Kim B.R."/>
<person name="Park S.Y."/>
</authorList>
<dbReference type="PubMed" id="21893193"/>
<dbReference type="DOI" id="10.1016/j.cellsig.2011.08.013"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PDCD6</scope>
</reference>
<reference key="46">
<citation type="journal article" date="2013" name="Antioxid. Redox Signal." volume="19" first="448" last="464">
<title>VEGFR2 functions as an H(2)S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells.</title>
<authorList>
<person name="Tao B.B."/>
<person name="Liu S.Y."/>
<person name="Zhang C.C."/>
<person name="Fu W."/>
<person name="Cai W.J."/>
<person name="Wang Y."/>
<person name="Shen Q."/>
<person name="Wang M.J."/>
<person name="Chen Y."/>
<person name="Zhang L.J."/>
<person name="Zhu Y.Z."/>
<person name="Zhu Y.C."/>
</authorList>
<dbReference type="PubMed" id="23199280"/>
<dbReference type="DOI" id="10.1089/ars.2012.4565"/>
</citation>
<scope>ENZYME REGULATION</scope>
<scope>REDOX-ACTIVE DISULFIDE BOND</scope>
<scope>MUTAGENESIS OF CYS-1045</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2013" name="Circulation" volume="127" first="1712" last="1722">
<title>Vascular endothelial cell growth-activated XBP1 splicing in endothelial cells is crucial for angiogenesis.</title>
<authorList>
<person name="Zeng L."/>
<person name="Xiao Q."/>
<person name="Chen M."/>
<person name="Margariti A."/>
<person name="Martin D."/>
<person name="Ivetic A."/>
<person name="Xu H."/>
<person name="Mason J."/>
<person name="Wang W."/>
<person name="Cockerill G."/>
<person name="Mori K."/>
<person name="Li J.Y."/>
<person name="Chien S."/>
<person name="Hu Y."/>
<person name="Xu Q."/>
</authorList>
<dbReference type="PubMed" id="23529610"/>
<dbReference type="DOI" id="10.1161/CIRCULATIONAHA.112.001337"/>
</citation>
<scope>INTERACTION WITH ERN1</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="48">
<citation type="journal article" date="1999" name="Structure" volume="7" first="319" last="330">
<title>Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.</title>
<authorList>
<person name="McTigue M.A."/>
<person name="Wickersham J.A."/>
<person name="Pinko C."/>
<person name="Showalter R.E."/>
<person name="Parast C.V."/>
<person name="Tempczyk-Russell A."/>
<person name="Gehring M.R."/>
<person name="Mroczkowski B."/>
<person name="Kan C.-C."/>
<person name="Villafranca J.E."/>
<person name="Appelt K."/>
</authorList>
<dbReference type="PubMed" id="10368301"/>
<dbReference type="DOI" id="10.1016/S0969-2126(99)80042-2"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 806-1171</scope>
<scope>FUNCTION</scope>
<scope>PHOSPHORYLATION AT TYR-1059</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2005" name="Bioorg. Med. Chem. Lett." volume="15" first="2203" last="2207">
<title>Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.</title>
<authorList>
<person name="Miyazaki Y."/>
<person name="Matsunaga S."/>
<person name="Tang J."/>
<person name="Maeda Y."/>
<person name="Nakano M."/>
<person name="Philippe R.J."/>
<person name="Shibahara M."/>
<person name="Liu W."/>
<person name="Sato H."/>
<person name="Wang L."/>
<person name="Nolte R.T."/>
</authorList>
<dbReference type="PubMed" id="15837294"/>
<dbReference type="DOI" id="10.1016/j.bmcl.2005.03.034"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) OF 806-1171 IN COMPLEX WITH SYNTHETIC INHIBITOR</scope>
</reference>
<reference key="50">
<citation type="journal article" date="2007" name="J. Med. Chem." volume="50" first="611" last="626">
<title>Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.</title>
<authorList>
<person name="Hodous B.L."/>
<person name="Geuns-Meyer S.D."/>
<person name="Hughes P.E."/>
<person name="Albrecht B.K."/>
<person name="Bellon S."/>
<person name="Bready J."/>
<person name="Caenepeel S."/>
<person name="Cee V.J."/>
<person name="Chaffee S.C."/>
<person name="Coxon A."/>
<person name="Emery M."/>
<person name="Fretland J."/>
<person name="Gallant P."/>
<person name="Gu Y."/>
<person name="Hoffman D."/>
<person name="Johnson R.E."/>
<person name="Kendall R."/>
<person name="Kim J.L."/>
<person name="Long A.M."/>
<person name="Morrison M."/>
<person name="Olivieri P.R."/>
<person name="Patel V.F."/>
<person name="Polverino A."/>
<person name="Rose P."/>
<person name="Tempest P."/>
<person name="Wang L."/>
<person name="Whittington D.A."/>
<person name="Zhao H."/>
</authorList>
<dbReference type="PubMed" id="17253678"/>
<dbReference type="DOI" id="10.1021/jm061107l"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 815-1171 IN COMPLEX WITH SYNTHETIC INHIBITOR</scope>
</reference>
<reference key="51">
<citation type="journal article" date="2008" name="J. Med. Chem." volume="51" first="3814" last="3824">
<title>Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.</title>
<authorList>
<person name="Peifer C."/>
<person name="Selig R."/>
<person name="Kinkel K."/>
<person name="Ott D."/>
<person name="Totzke F."/>
<person name="Schaechtele C."/>
<person name="Heidenreich R."/>
<person name="Roecken M."/>
<person name="Schollmeyer D."/>
<person name="Laufer S."/>
</authorList>
<dbReference type="PubMed" id="18529047"/>
<dbReference type="DOI" id="10.1021/jm8001185"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 806-1171 IN COMPLEX WITH SYNTHETIC INHIBITOR</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="52">
<citation type="journal article" date="2010" name="Proc. Natl. Acad. Sci. U.S.A." volume="107" first="1906" last="1911">
<title>Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling.</title>
<authorList>
<person name="Yang Y."/>
<person name="Xie P."/>
<person name="Opatowsky Y."/>
<person name="Schlessinger J."/>
</authorList>
<dbReference type="PubMed" id="20080685"/>
<dbReference type="DOI" id="10.1073/pnas.0914052107"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 657-764</scope>
<scope>SUBUNIT</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>FUNCTION IN VEGFA SIGNALING AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1</scope>
<scope>MUTAGENESIS OF ARG-726 AND ASP-731</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2010" name="Proc. Natl. Acad. Sci. U.S.A." volume="107" first="2425" last="2430">
<title>Structural determinants of growth factor binding and specificity by VEGF receptor 2.</title>
<authorList>
<person name="Leppanen V.M."/>
<person name="Prota A.E."/>
<person name="Jeltsch M."/>
<person name="Anisimov A."/>
<person name="Kalkkinen N."/>
<person name="Strandin T."/>
<person name="Lankinen H."/>
<person name="Goldman A."/>
<person name="Ballmer-Hofer K."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="20145116"/>
<dbReference type="DOI" id="10.1073/pnas.0914318107"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 120-326 IN COMPLEX WITH VEGFC</scope>
<scope>INTERACTION WITH VEGFC</scope>
<scope>DOMAIN</scope>
<scope>DISULFIDE BONDS</scope>
<scope>GLYCOSYLATION AT ASN-143; ASN-245 AND ASN-318</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2011" name="Structure" volume="19" first="1097" last="1107">
<title>The structural basis for the function of two anti-VEGF receptor 2 antibodies.</title>
<authorList>
<person name="Franklin M.C."/>
<person name="Navarro E.C."/>
<person name="Wang Y."/>
<person name="Patel S."/>
<person name="Singh P."/>
<person name="Zhang Y."/>
<person name="Persaud K."/>
<person name="Bari A."/>
<person name="Griffith H."/>
<person name="Shen L."/>
<person name="Balderes P."/>
<person name="Kussie P."/>
</authorList>
<dbReference type="PubMed" id="21827946"/>
<dbReference type="DOI" id="10.1016/j.str.2011.01.019"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 220-338 IN COMPLEX WITH ANTIBODY FRAGMENT</scope>
<scope>DISULFIDE BOND</scope>
<scope>GLYCOSYLATION AT ASN-245 AND ASN-318</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2002" name="Genes Chromosomes Cancer" volume="33" first="295" last="303">
<title>Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.</title>
<authorList>
<person name="Walter J.W."/>
<person name="North P.E."/>
<person name="Waner M."/>
<person name="Mizeracki A."/>
<person name="Blei F."/>
<person name="Walker J.W.T."/>
<person name="Reinisch J.F."/>
<person name="Marchuk D.A."/>
</authorList>
<dbReference type="PubMed" id="11807987"/>
<dbReference type="DOI" id="10.1002/gcc.10028"/>
</citation>
<scope>VARIANT HCI SER-1147</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2006" name="Science" volume="314" first="268" last="274">
<title>The consensus coding sequences of human breast and colorectal cancers.</title>
<authorList>
<person name="Sjoeblom T."/>
<person name="Jones S."/>
<person name="Wood L.D."/>
<person name="Parsons D.W."/>
<person name="Lin J."/>
<person name="Barber T.D."/>
<person name="Mandelker D."/>
<person name="Leary R.J."/>
<person name="Ptak J."/>
<person name="Silliman N."/>
<person name="Szabo S."/>
<person name="Buckhaults P."/>
<person name="Farrell C."/>
<person name="Meeh P."/>
<person name="Markowitz S.D."/>
<person name="Willis J."/>
<person name="Dawson D."/>
<person name="Willson J.K.V."/>
<person name="Gazdar A.F."/>
<person name="Hartigan J."/>
<person name="Wu L."/>
<person name="Liu C."/>
<person name="Parmigiani G."/>
<person name="Park B.H."/>
<person name="Bachman K.E."/>
<person name="Papadopoulos N."/>
<person name="Vogelstein B."/>
<person name="Kinzler K.W."/>
<person name="Velculescu V.E."/>
</authorList>
<dbReference type="PubMed" id="16959974"/>
<dbReference type="DOI" id="10.1126/science.1133427"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] LEU-275 AND ARG-873</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANT HCI ARG-482</scope>
<scope>VARIANTS [LARGE SCALE ANALYSIS] ARG-2; MET-136; GLY-248; ILE-297; VAL-462; HIS-472; ARG-539; MET-689; ASN-814 AND THR-1065</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2008" name="Nat. Med." volume="14" first="1236" last="1246">
<title>Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.</title>
<authorList>
<person name="Jinnin M."/>
<person name="Medici D."/>
<person name="Park L."/>
<person name="Limaye N."/>
<person name="Liu Y."/>
<person name="Boscolo E."/>
<person name="Bischoff J."/>
<person name="Vikkula M."/>
<person name="Boye E."/>
<person name="Olsen B.R."/>
</authorList>
<dbReference type="PubMed" id="18931684"/>
<dbReference type="DOI" id="10.1038/nm.1877"/>
</citation>
<scope>VARIANT HCI ARG-482</scope>
</reference>
<comment type="function">
<text evidence="20 21 23 24 26 28 29 30 33 36 39 41 47 48 49 51 52 54 57 58 59 60">Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.</text>
</comment>
<comment type="catalytic activity">
<text evidence="18 19 20">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="19 20 30 55">Present in an inactive conformation in the absence of bound ligand. Binding of VEGFA, VEGFC or VEGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by the small molecule PTK inhibitor SU5614 ((3Z)-5-Chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one). May be regulated by hydrogen sulfide (H(2)S) levels via a H(2)S-sensitive intracellular disulfide bond.</text>
</comment>
<comment type="subunit">
<text evidence="20 22 26 27 28 29 30 32 33 36 38 41 42 45 47 49 50 51 52 53 54 56 58">Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD ligands; monomeric in the absence of bound ligands. Can also form heterodimers with FLT1/VEGFR1 and FLT4/VEGFR2. Interacts (tyrosine phosphorylated) with LFYN, NCK1, PLCG1. Interacts (tyrosine-phosphorylated active form preferentially) with DAB2IP (via C2 domain and active form preferentially); the interaction occurs at the late phase of VEGFA response and inhibits KDR/VEGFR2 activity. Interacts with SHBSH2D2A/TSAD, GRB2, MYOF, CBL and PDCD6. Interacts with HIV-1 Tat (PubMed:10102632, PubMed:10590123, PubMed:12649282, PubMed:12881528, PubMed:1417831, PubMed:15026417, PubMed:15215251, PubMed:15837294, PubMed:15962004, PubMed:16966330, PubMed:17253678, PubMed:18529047, PubMed:18593464, PubMed:19033661, PubMed:19668192, PubMed:20080685, PubMed:20145116, PubMed:20224550, PubMed:20705758, PubMed:21827946, PubMed:21893193, PubMed:9160888). Interacts (via C-terminus domain) with ERN1 (via kinase domain); the interaction is facilitated in a XBP1 isoform 1- and vascular endothelial growth factor (VEGF)-dependent manner in endothelial cells (PubMed:23529610).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1005487"/>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-886">
<id>P46108</id>
<label>CRK</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1005467">
<id>P35916</id>
<label>FLT4</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-944395">
<id>O60565</id>
<label>GREM1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-947664">
<id>P98160</id>
<label>HSPG2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-702960">
<id>P17301</id>
<label>ITGA2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1048875">
<id>P09382</id>
<label>LGALS1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1039152">
<id>P08581</id>
<label>MET</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-389883">
<id>P16333</id>
<label>NCK1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1187100">
<id>O14786</id>
<label>NRP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-352915">
<id>O75340</id>
<label>PDCD6</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-641237">
<id>P09619</id>
<label>PDGFRB</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-2264500">
<id>Q12913</id>
<label>PTPRJ</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-621482">
<id>P12931</id>
<label>SRC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1026643">
<id>P15692</id>
<label>VEGFA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-1026691">
<id>P15692-4</id>
<label>VEGFA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>8</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-15622828">
<id>Q9MYV3-3</id>
<label>VEGFA</label>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005487"/>
<interactant intactId="EBI-3405539">
<id>P49767</id>
<label>VEGFC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="13">Cell junction</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="56">Endoplasmic reticulum</location>
</subcellularLocation>
<text evidence="13 56">Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610).</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 1</molecule>
<subcellularLocation>
<location>Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location>Nucleus</location>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasmic vesicle</location>
</subcellularLocation>
<subcellularLocation>
<location>Early endosome</location>
</subcellularLocation>
<text>Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 2</molecule>
<subcellularLocation>
<location evidence="63">Secreted</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 3</molecule>
<subcellularLocation>
<location>Secreted</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P35968-1</id>
<name>1</name>
<name>mbVegfr-2</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P35968-2</id>
<name>2</name>
<name>sVegfr-2</name>
<sequence type="described" ref="VSP_041988 VSP_041989"/>
</isoform>
<isoform>
<id>P35968-3</id>
<name>3</name>
<name>VEGFR2-712</name>
<sequence type="described" ref="VSP_041990 VSP_041991"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="47">Detected in cornea (at protein level). Widely expressed.</text>
</comment>
<comment type="domain">
<text evidence="50">The second and third Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFC binding.</text>
</comment>
<comment type="PTM">
<text evidence="50 53 58">N-glycosylated.</text>
</comment>
<comment type="PTM">
<text evidence="26 37 48">Ubiquitinated. Tyrosine phosphorylation of the receptor promotes its poly-ubiquitination, leading to its degradation via the proteasome or lysosomal proteases.</text>
</comment>
<comment type="PTM">
<text evidence="19 20 21 24 30 33 44 46">Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-951 is important for interaction with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for interaction with NCK1 and FYN. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.</text>
</comment>
<comment type="PTM">
<text>The inhibitory disulfide bond between Cys-1024 and Cys-1045 may serve as a specific molecular switch for H(2)S-induced modification that regulates VEGFR2 function.</text>
</comment>
<comment type="disease" evidence="25 40 43">
<disease id="DI-02546">
<name>Hemangioma, capillary infantile</name>
<acronym>HCI</acronym>
<description>A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring.</description>
<dbReference type="MIM" id="602089"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease">
<text>Plays a major role in tumor angiogenesis. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.</text>
</comment>
<comment type="similarity">
<text evidence="17">Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.</text>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="EU826563">
<property type="protein sequence ID" value="ACF47599.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="FJ899739">
<property type="protein sequence ID" value="ACR78514.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF035121">
<property type="protein sequence ID" value="AAB88005.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF063658">
<property type="protein sequence ID" value="AAC16450.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC021220">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC111194">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC131822">
<property type="protein sequence ID" value="AAI31823.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="L04947">
<property type="protein sequence ID" value="AAA59459.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="X61656">
<property type="protein sequence ID" value="CAA43837.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="X89776">
<property type="protein sequence ID" value="CAA61916.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS3497.1">
<molecule id="P35968-1"/>
</dbReference>
<dbReference type="PIR" id="JC1402">
<property type="entry name" value="JC1402"/>
</dbReference>
<dbReference type="RefSeq" id="NP_002244.1">
<molecule id="P35968-1"/>
<property type="nucleotide sequence ID" value="NM_002253.2"/>
</dbReference>
<dbReference type="UniGene" id="Hs.479756"/>
<dbReference type="PDB" id="1VR2">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="1Y6A">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="1Y6B">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="1YWN">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.71"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="2M59">
<property type="method" value="NMR"/>
<property type="chains" value="A/B=759-795"/>
</dbReference>
<dbReference type="PDB" id="2MET">
<property type="method" value="NMR"/>
<property type="chains" value="A/B/C=759-795"/>
</dbReference>
<dbReference type="PDB" id="2MEU">
<property type="method" value="NMR"/>
<property type="chains" value="A/B=759-795"/>
</dbReference>
<dbReference type="PDB" id="2OH4">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.05"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="2P2H">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.95"/>
<property type="chains" value="A=815-1171"/>
</dbReference>
<dbReference type="PDB" id="2P2I">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="2QU5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.95"/>
<property type="chains" value="A=815-1171"/>
</dbReference>
<dbReference type="PDB" id="2QU6">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="2RL5">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.65"/>
<property type="chains" value="A=815-1171"/>
</dbReference>
<dbReference type="PDB" id="2X1W">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="L/M/N/O=120-326"/>
</dbReference>
<dbReference type="PDB" id="2X1X">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.10"/>
<property type="chains" value="R=120-326"/>
</dbReference>
<dbReference type="PDB" id="2XIR">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.50"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="3B8Q">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.75"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3B8R">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3BE2">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.75"/>
<property type="chains" value="A=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3C7Q">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.10"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="3CJF">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.15"/>
<property type="chains" value="A=806-1168"/>
</dbReference>
<dbReference type="PDB" id="3CJG">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.25"/>
<property type="chains" value="A=806-1168"/>
</dbReference>
<dbReference type="PDB" id="3CP9">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3CPB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3CPC">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.40"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3DTW">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3EFL">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="A/B=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3EWH">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.60"/>
<property type="chains" value="A=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3KVQ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A=657-764"/>
</dbReference>
<dbReference type="PDB" id="3S35">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.20"/>
<property type="chains" value="X=220-338"/>
</dbReference>
<dbReference type="PDB" id="3S36">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="X=220-338"/>
</dbReference>
<dbReference type="PDB" id="3S37">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="X=220-338"/>
</dbReference>
<dbReference type="PDB" id="3U6J">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.15"/>
<property type="chains" value="A=815-1171"/>
</dbReference>
<dbReference type="PDB" id="3V2A">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="R=2-764"/>
</dbReference>
<dbReference type="PDB" id="3V6B">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="R=132-548"/>
</dbReference>
<dbReference type="PDB" id="3VHE">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.55"/>
<property type="chains" value="A=811-1169"/>
</dbReference>
<dbReference type="PDB" id="3VHK">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.49"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="3VID">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.30"/>
<property type="chains" value="A=813-1168"/>
</dbReference>
<dbReference type="PDB" id="3VNT">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.64"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="3VO3">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.52"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="3WZD">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.57"/>
<property type="chains" value="A=814-1172"/>
</dbReference>
<dbReference type="PDB" id="3WZE">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=814-1172"/>
</dbReference>
<dbReference type="PDB" id="4AG8">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.95"/>
<property type="chains" value="A=806-1171"/>
</dbReference>
<dbReference type="PDB" id="4AGC">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=787-1171"/>
</dbReference>
<dbReference type="PDB" id="4AGD">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.81"/>
<property type="chains" value="A=787-1171"/>
</dbReference>
<dbReference type="PDB" id="4ASD">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.03"/>
<property type="chains" value="A=787-1171"/>
</dbReference>
<dbReference type="PDB" id="4ASE">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.83"/>
<property type="chains" value="A=787-1171"/>
</dbReference>
<dbReference type="PDB" id="5EW3">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/B=806-1171"/>
</dbReference>
<dbReference type="PDBsum" id="1VR2"/>
<dbReference type="PDBsum" id="1Y6A"/>
<dbReference type="PDBsum" id="1Y6B"/>
<dbReference type="PDBsum" id="1YWN"/>
<dbReference type="PDBsum" id="2M59"/>
<dbReference type="PDBsum" id="2MET"/>
<dbReference type="PDBsum" id="2MEU"/>
<dbReference type="PDBsum" id="2OH4"/>
<dbReference type="PDBsum" id="2P2H"/>
<dbReference type="PDBsum" id="2P2I"/>
<dbReference type="PDBsum" id="2QU5"/>
<dbReference type="PDBsum" id="2QU6"/>
<dbReference type="PDBsum" id="2RL5"/>
<dbReference type="PDBsum" id="2X1W"/>
<dbReference type="PDBsum" id="2X1X"/>
<dbReference type="PDBsum" id="2XIR"/>
<dbReference type="PDBsum" id="3B8Q"/>
<dbReference type="PDBsum" id="3B8R"/>
<dbReference type="PDBsum" id="3BE2"/>
<dbReference type="PDBsum" id="3C7Q"/>
<dbReference type="PDBsum" id="3CJF"/>
<dbReference type="PDBsum" id="3CJG"/>
<dbReference type="PDBsum" id="3CP9"/>
<dbReference type="PDBsum" id="3CPB"/>
<dbReference type="PDBsum" id="3CPC"/>
<dbReference type="PDBsum" id="3DTW"/>
<dbReference type="PDBsum" id="3EFL"/>
<dbReference type="PDBsum" id="3EWH"/>
<dbReference type="PDBsum" id="3KVQ"/>
<dbReference type="PDBsum" id="3S35"/>
<dbReference type="PDBsum" id="3S36"/>
<dbReference type="PDBsum" id="3S37"/>
<dbReference type="PDBsum" id="3U6J"/>
<dbReference type="PDBsum" id="3V2A"/>
<dbReference type="PDBsum" id="3V6B"/>
<dbReference type="PDBsum" id="3VHE"/>
<dbReference type="PDBsum" id="3VHK"/>
<dbReference type="PDBsum" id="3VID"/>
<dbReference type="PDBsum" id="3VNT"/>
<dbReference type="PDBsum" id="3VO3"/>
<dbReference type="PDBsum" id="3WZD"/>
<dbReference type="PDBsum" id="3WZE"/>
<dbReference type="PDBsum" id="4AG8"/>
<dbReference type="PDBsum" id="4AGC"/>
<dbReference type="PDBsum" id="4AGD"/>
<dbReference type="PDBsum" id="4ASD"/>
<dbReference type="PDBsum" id="4ASE"/>
<dbReference type="PDBsum" id="5EW3"/>
<dbReference type="ProteinModelPortal" id="P35968"/>
<dbReference type="SMR" id="P35968"/>
<dbReference type="BioGrid" id="109992">
<property type="interactions" value="55"/>
</dbReference>
<dbReference type="CORUM" id="P35968"/>
<dbReference type="DIP" id="DIP-486N"/>
<dbReference type="IntAct" id="P35968">
<property type="interactions" value="38"/>
</dbReference>
<dbReference type="MINT" id="MINT-127732"/>
<dbReference type="STRING" id="9606.ENSP00000263923"/>
<dbReference type="BindingDB" id="P35968"/>
<dbReference type="ChEMBL" id="CHEMBL279"/>
<dbReference type="DrugBank" id="DB07528">
<property type="generic name" value="3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one"/>
</dbReference>
<dbReference type="DrugBank" id="DB06938">
<property type="generic name" value="4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide"/>
</dbReference>
<dbReference type="DrugBank" id="DB06080">
<property type="generic name" value="ABT-869"/>
</dbReference>
<dbReference type="DrugBank" id="DB06626">
<property type="generic name" value="Axitinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB04849">
<property type="generic name" value="AZD2171"/>
</dbReference>
<dbReference type="DrugBank" id="DB08875">
<property type="generic name" value="Cabozantinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05198">
<property type="generic name" value="CYC116"/>
</dbReference>
<dbReference type="DrugBank" id="DB06101">
<property type="generic name" value="IMC-1C11"/>
</dbReference>
<dbReference type="DrugBank" id="DB09078">
<property type="generic name" value="Lenvatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB07183">
<property type="generic name" value="N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide"/>
</dbReference>
<dbReference type="DrugBank" id="DB09079">
<property type="generic name" value="Nintedanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB06589">
<property type="generic name" value="Pazopanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB08901">
<property type="generic name" value="Ponatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05578">
<property type="generic name" value="Ramucirumab"/>
</dbReference>
<dbReference type="DrugBank" id="DB08896">
<property type="generic name" value="Regorafenib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00398">
<property type="generic name" value="Sorafenib"/>
</dbReference>
<dbReference type="DrugBank" id="DB01268">
<property type="generic name" value="Sunitinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05075">
<property type="generic name" value="TG100801"/>
</dbReference>
<dbReference type="DrugBank" id="DB04879">
<property type="generic name" value="Vatalanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05153">
<property type="generic name" value="XL184"/>
</dbReference>
<dbReference type="DrugBank" id="DB05146">
<property type="generic name" value="XL820"/>
</dbReference>
<dbReference type="DrugBank" id="DB05030">
<property type="generic name" value="XL880"/>
</dbReference>
<dbReference type="DrugBank" id="DB05014">
<property type="generic name" value="XL999"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1813"/>
<dbReference type="iPTMnet" id="P35968"/>
<dbReference type="PhosphoSitePlus" id="P35968"/>
<dbReference type="BioMuta" id="KDR"/>
<dbReference type="DMDM" id="9087218"/>
<dbReference type="EPD" id="P35968"/>
<dbReference type="MaxQB" id="P35968"/>
<dbReference type="PaxDb" id="P35968"/>
<dbReference type="PeptideAtlas" id="P35968"/>
<dbReference type="PRIDE" id="P35968"/>
<dbReference type="DNASU" id="3791"/>
<dbReference type="Ensembl" id="ENST00000263923">
<molecule id="P35968-1"/>
<property type="protein sequence ID" value="ENSP00000263923"/>
<property type="gene ID" value="ENSG00000128052"/>
</dbReference>
<dbReference type="GeneID" id="3791"/>
<dbReference type="KEGG" id="hsa:3791"/>
<dbReference type="UCSC" id="uc003has.4">
<molecule id="P35968-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="3791"/>
<dbReference type="DisGeNET" id="3791"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000128052.8"/>
<dbReference type="GeneCards" id="KDR"/>
<dbReference type="HGNC" id="HGNC:6307">
<property type="gene designation" value="KDR"/>
</dbReference>
<dbReference type="HPA" id="CAB004028"/>
<dbReference type="MalaCards" id="KDR"/>
<dbReference type="MIM" id="191306">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="602089">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P35968"/>
<dbReference type="OpenTargets" id="ENSG00000128052"/>
<dbReference type="Orphanet" id="91415">
<property type="disease" value="Familial capillary hemangioma"/>
</dbReference>
<dbReference type="PharmGKB" id="PA30086"/>
<dbReference type="eggNOG" id="KOG0200">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118923"/>
<dbReference type="HOVERGEN" id="HBG053432"/>
<dbReference type="InParanoid" id="P35968"/>
<dbReference type="KO" id="K05098"/>
<dbReference type="OMA" id="MFFWLLL"/>
<dbReference type="OrthoDB" id="EOG091G01TL"/>
<dbReference type="PhylomeDB" id="P35968"/>
<dbReference type="TreeFam" id="TF325768"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-194306">
<property type="pathway name" value="Neurophilin interactions with VEGF and VEGFR"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-195399">
<property type="pathway name" value="VEGF binds to VEGFR leading to receptor dimerization"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-216083">
<property type="pathway name" value="Integrin cell surface interactions"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-4420097">
<property type="pathway name" value="VEGFA-VEGFR2 Pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5218921">
<property type="pathway name" value="VEGFR2 mediated cell proliferation"/>
</dbReference>
<dbReference type="SignaLink" id="P35968"/>
<dbReference type="SIGNOR" id="P35968"/>
<dbReference type="EvolutionaryTrace" id="P35968"/>
<dbReference type="GeneWiki" id="Kinase_insert_domain_receptor"/>
<dbReference type="GenomeRNAi" id="3791"/>
<dbReference type="PRO" id="PR:P35968"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 4"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000128052"/>
<dbReference type="CleanEx" id="HS_KDR"/>
<dbReference type="ExpressionAtlas" id="P35968">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P35968">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0030054">
<property type="term" value="C:cell junction"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005769">
<property type="term" value="C:early endosome"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005768">
<property type="term" value="C:endosome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005576">
<property type="term" value="C:extracellular region"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045121">
<property type="term" value="C:membrane raft"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097443">
<property type="term" value="C:sorting endosome"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0019838">
<property type="term" value="F:growth factor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051879">
<property type="term" value="F:Hsp90 protein binding"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0042802">
<property type="term" value="F:identical protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="IntAct"/>
</dbReference>
<dbReference type="GO" id="GO:0005178">
<property type="term" value="F:integrin binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0004713">
<property type="term" value="F:protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004716">
<property type="term" value="F:signal transducer, downstream of receptor, with protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0004714">
<property type="term" value="F:transmembrane receptor protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0038085">
<property type="term" value="F:vascular endothelial growth factor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005021">
<property type="term" value="F:vascular endothelial growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001525">
<property type="term" value="P:angiogenesis"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0035584">
<property type="term" value="P:calcium-mediated signaling using intracellular calcium source"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0002042">
<property type="term" value="P:cell migration involved in sprouting angiogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1904881">
<property type="term" value="P:cellular response to hydrogen sulfide"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0035924">
<property type="term" value="P:cellular response to vascular endothelial growth factor stimulus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035162">
<property type="term" value="P:embryonic hemopoiesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003158">
<property type="term" value="P:endothelium development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070371">
<property type="term" value="P:ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030198">
<property type="term" value="P:extracellular matrix organization"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000352">
<property type="term" value="P:negative regulation of endothelial cell apoptotic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010629">
<property type="term" value="P:negative regulation of gene expression"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0038083">
<property type="term" value="P:peptidyl-tyrosine autophosphorylation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045766">
<property type="term" value="P:positive regulation of angiogenesis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043536">
<property type="term" value="P:positive regulation of blood vessel endothelial cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030335">
<property type="term" value="P:positive regulation of cell migration"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0038033">
<property type="term" value="P:positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010595">
<property type="term" value="P:positive regulation of endothelial cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001938">
<property type="term" value="P:positive regulation of endothelial cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070374">
<property type="term" value="P:positive regulation of ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051894">
<property type="term" value="P:positive regulation of focal adhesion assembly"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0016239">
<property type="term" value="P:positive regulation of macroautophagy"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0043410">
<property type="term" value="P:positive regulation of MAPK cascade"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051901">
<property type="term" value="P:positive regulation of mitochondrial depolarization"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0090141">
<property type="term" value="P:positive regulation of mitochondrial fission"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0051770">
<property type="term" value="P:positive regulation of nitric-oxide synthase biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014068">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050927">
<property type="term" value="P:positive regulation of positive chemotaxis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001934">
<property type="term" value="P:positive regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2001214">
<property type="term" value="P:positive regulation of vasculogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043491">
<property type="term" value="P:protein kinase B signaling"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008360">
<property type="term" value="P:regulation of cell shape"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007169">
<property type="term" value="P:transmembrane receptor protein tyrosine kinase signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0048010">
<property type="term" value="P:vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001570">
<property type="term" value="P:vasculogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016032">
<property type="term" value="P:viral process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="8"/>
</dbReference>
<dbReference type="InterPro" id="IPR007110">
<property type="entry name" value="Ig-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR036179">
<property type="entry name" value="Ig-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR013098">
<property type="entry name" value="Ig_I-set"/>
</dbReference>
<dbReference type="InterPro" id="IPR003599">
<property type="entry name" value="Ig_sub"/>
</dbReference>
<dbReference type="InterPro" id="IPR003598">
<property type="entry name" value="Ig_sub2"/>
</dbReference>
<dbReference type="InterPro" id="IPR013151">
<property type="entry name" value="Immunoglobulin"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001824">
<property type="entry name" value="Tyr_kinase_rcpt_3_CS"/>
</dbReference>
<dbReference type="InterPro" id="IPR009136">
<property type="entry name" value="VEGFR2_rcpt"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR24416:SF45">
<property type="entry name" value="PTHR24416:SF45"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="Pfam" id="PF07679">
<property type="entry name" value="I-set"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="Pfam" id="PF00047">
<property type="entry name" value="ig"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR01834">
<property type="entry name" value="VEGFRECEPTR2"/>
</dbReference>
<dbReference type="SMART" id="SM00409">
<property type="entry name" value="IG"/>
<property type="match status" value="7"/>
</dbReference>
<dbReference type="SMART" id="SM00408">
<property type="entry name" value="IGc2"/>
<property type="match status" value="5"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48726">
<property type="entry name" value="SSF48726"/>
<property type="match status" value="7"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS50835">
<property type="entry name" value="IG_LIKE"/>
<property type="match status" value="5"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00240">
<property type="entry name" value="RECEPTOR_TYR_KIN_III"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0037">Angiogenesis</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-0965">Cell junction</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0968">Cytoplasmic vesicle</keyword>
<keyword id="KW-0217">Developmental protein</keyword>
<keyword id="KW-0221">Differentiation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0967">Endosome</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0945">Host-virus interaction</keyword>
<keyword id="KW-0393">Immunoglobulin domain</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0964">Secreted</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="signal peptide" evidence="15">
<location>
<begin position="1"/>
<end position="19"/>
</location>
</feature>
<feature type="chain" description="Vascular endothelial growth factor receptor 2" id="PRO_0000016771">
<location>
<begin position="20"/>
<end position="1356"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="15">
<location>
<begin position="20"/>
<end position="764"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="15">
<location>
<begin position="765"/>
<end position="785"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="15">
<location>
<begin position="786"/>
<end position="1356"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 1">
<location>
<begin position="46"/>
<end position="110"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 2">
<location>
<begin position="141"/>
<end position="207"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 3">
<location>
<begin position="224"/>
<end position="320"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 4">
<location>
<begin position="328"/>
<end position="414"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 5">
<location>
<begin position="421"/>
<end position="548"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 6">
<location>
<begin position="551"/>
<end position="660"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 7">
<location>
<begin position="667"/>
<end position="753"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="17">
<location>
<begin position="834"/>
<end position="1162"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="63">
<location>
<begin position="840"/>
<end position="848"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="17 18">
<location>
<position position="1028"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="63">
<location>
<position position="868"/>
</location>
</feature>
<feature type="site" description="Interaction with SHB" evidence="13">
<location>
<position position="1175"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine" evidence="39 44">
<location>
<position position="801"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="33 44 46">
<location>
<position position="951"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="12">
<location>
<position position="982"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="12">
<location>
<position position="984"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="20 44">
<location>
<position position="996"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="19 20 30 33 44">
<location>
<position position="1054"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="19 20 21 30 33 44">
<location>
<position position="1059"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="24 44 46">
<location>
<position position="1175"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="24 33 44 46">
<location>
<position position="1214"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="14">
<location>
<position position="1231"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="14">
<location>
<position position="1235"/>
</location>
</feature>
<feature type="modified residue" description="Phosphothreonine" evidence="14">
<location>
<position position="1238"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="33">
<location>
<position position="1305"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="33">
<location>
<position position="1309"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="33">
<location>
<position position="1319"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="46"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="66"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="96"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="50">
<location>
<position position="143"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="158"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="50 53">
<location>
<position position="245"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="50 53">
<location>
<position position="318"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="374"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="395"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="511"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="523"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="580"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="613"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="619"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="631"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="675"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="704"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="15">
<location>
<position position="721"/>
</location>
</feature>
<feature type="disulfide bond" evidence="16">
<location>
<begin position="53"/>
<end position="103"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="150"/>
<end position="200"/>
</location>
</feature>
<feature type="disulfide bond">
<location>
<begin position="246"/>
<end position="307"/>
</location>
</feature>
<feature type="disulfide bond" evidence="16">
<location>
<begin position="445"/>
<end position="530"/>
</location>
</feature>
<feature type="disulfide bond" evidence="16">
<location>
<begin position="571"/>
<end position="642"/>
</location>
</feature>
<feature type="disulfide bond" evidence="16">
<location>
<begin position="688"/>
<end position="737"/>
</location>
</feature>
<feature type="disulfide bond" description="Redox-active">
<location>
<begin position="1024"/>
<end position="1045"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_041988" evidence="62">
<original>ERVAPTITGNLENQTT</original>
<variation>GRETILDHCAEAVGMP</variation>
<location>
<begin position="663"/>
<end position="678"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_041989" evidence="62">
<location>
<begin position="679"/>
<end position="1356"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_041990" evidence="61">
<original>G</original>
<variation>E</variation>
<location>
<position position="712"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_041991" evidence="61">
<location>
<begin position="713"/>
<end position="1356"/>
</location>
</feature>
<feature type="sequence variant" description="In a lung adenocarcinoma sample; somatic mutation." id="VAR_042053" evidence="40">
<original>Q</original>
<variation>R</variation>
<location>
<position position="2"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35636987." id="VAR_042054" evidence="40">
<original>V</original>
<variation>M</variation>
<location>
<position position="136"/>
</location>
</feature>
<feature type="sequence variant" description="In a renal clear cell carcinoma sample; somatic mutation." id="VAR_042055" evidence="40">
<original>A</original>
<variation>G</variation>
<location>
<position position="248"/>
</location>
</feature>
<feature type="sequence variant" description="In a colorectal cancer sample; somatic mutation." id="VAR_036126" evidence="35">
<original>R</original>
<variation>L</variation>
<location>
<position position="275"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2305948." id="VAR_022071" evidence="40">
<original>V</original>
<variation>I</variation>
<location>
<position position="297"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56286620." id="VAR_042056" evidence="40">
<original>L</original>
<variation>V</variation>
<location>
<position position="462"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1870377." id="VAR_020353" evidence="31 40">
<original>Q</original>
<variation>H</variation>
<location>
<position position="472"/>
</location>
</feature>
<feature type="sequence variant" description="In HCI; associated with disease susceptibility; expression of FLT1 in hemangioma endothelial cells is markedly reduced and KDR activity is increased compared to controls; low FLT1 expression in hemangioma cells is caused by reduced activity of a pathway involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation predicts to result in loss-of-function and disruption of the normal association of these molecules; dbSNP:rs34231037." id="VAR_042057" evidence="40 43">
<original>C</original>
<variation>R</variation>
<location>
<position position="482"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55716939." id="VAR_042058" evidence="40">
<original>G</original>
<variation>R</variation>
<location>
<position position="539"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34038364." id="VAR_042059" evidence="40">
<original>T</original>
<variation>M</variation>
<location>
<position position="689"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35603373." id="VAR_042060" evidence="40">
<original>D</original>
<variation>N</variation>
<location>
<position position="814"/>
</location>
</feature>
<feature type="sequence variant" description="Strongly reduced autophosphorylation and kinase activity; dbSNP:rs1139776." id="VAR_046679" evidence="19 34">
<original>V</original>
<variation>E</variation>
<location>
<position position="848"/>
</location>
</feature>
<feature type="sequence variant" description="In a colorectal cancer sample; somatic mutation." id="VAR_036127" evidence="35">
<original>G</original>
<variation>R</variation>
<location>
<position position="873"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs13129474." id="VAR_046680">
<original>V</original>
<variation>I</variation>
<location>
<position position="952"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56302315." id="VAR_042061" evidence="40">
<original>A</original>
<variation>T</variation>
<location>
<position position="1065"/>
</location>
</feature>
<feature type="sequence variant" description="In HCI; somatic mutation; dbSNP:rs121917766." id="VAR_063147" evidence="25">
<original>P</original>
<variation>S</variation>
<location>
<position position="1147"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation and activation of MAP kinases." evidence="49">
<original>R</original>
<variation>A</variation>
<location>
<position position="726"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation and activation of MAP kinases." evidence="49">
<original>D</original>
<variation>A</variation>
<location>
<position position="731"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes stimulation of nitric oxide synthesis." evidence="39">
<original>Y</original>
<variation>F</variation>
<location>
<position position="801"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of enzyme activity." evidence="24">
<original>K</original>
<variation>M</variation>
<location>
<position position="868"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes reorganization of the actin cytoskeleton and cell migration in response to VEGFA." evidence="33">
<original>Y</original>
<variation>F</variation>
<location>
<position position="951"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation. Reduces phosphorylation of PLCG1." evidence="20">
<original>Y</original>
<variation>F</variation>
<location>
<position position="996"/>
</location>
</feature>
<feature type="mutagenesis site" description="Significantly higher kinase activity." evidence="55">
<original>C</original>
<variation>A</variation>
<location>
<position position="1045"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1059." evidence="20">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1054"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1054." evidence="20">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1059"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes phosphorylation of PLCG1 and MAP kinases in response to VEGFA." evidence="24">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1175"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. Abolishes reorganization of the actin cytoskeleton in response to VEGFA." evidence="36">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1214"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 4; AAC16450." ref="4" evidence="63">
<original>Q</original>
<variation>E</variation>
<location>
<position position="2"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAA59459/CAA43837." ref="7" evidence="63">
<original>A</original>
<variation>T</variation>
<location>
<position position="772"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAA59459/CAA43837." ref="7" evidence="63">
<original>R</original>
<variation>G</variation>
<location>
<position position="787"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAA59459/CAA43837." ref="7" evidence="63">
<original>K</original>
<variation>N</variation>
<location>
<position position="835"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAA59459/CAA43837." ref="7" evidence="63">
<original>S</original>
<variation>T</variation>
<location>
<position position="1347"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="134"/>
<end position="138"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="145"/>
<end position="148"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="152"/>
<end position="154"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="159"/>
<end position="164"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="165"/>
<end position="167"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="168"/>
<end position="170"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="174"/>
<end position="176"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="178"/>
<end position="180"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="181"/>
<end position="183"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="184"/>
<end position="188"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="189"/>
<end position="191"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="192"/>
<end position="194"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="196"/>
<end position="202"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="214"/>
<end position="218"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="223"/>
<end position="230"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="234"/>
<end position="238"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="242"/>
<end position="250"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="257"/>
<end position="261"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="269"/>
<end position="272"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="279"/>
<end position="282"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="285"/>
<end position="296"/>
</location>
</feature>
<feature type="helix" evidence="6">
<location>
<begin position="299"/>
<end position="301"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="303"/>
<end position="310"/>
</location>
</feature>
<feature type="strand" evidence="6">
<location>
<begin position="315"/>
<end position="328"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="676"/>
<end position="679"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="684"/>
<end position="687"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="697"/>
<end position="706"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="713"/>
<end position="716"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="717"/>
<end position="720"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="721"/>
<end position="724"/>
</location>
</feature>
<feature type="helix" evidence="5">
<location>
<begin position="729"/>
<end position="731"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="733"/>
<end position="740"/>
</location>
</feature>
<feature type="strand" evidence="5">
<location>
<begin position="746"/>
<end position="755"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="760"/>
<end position="794"/>
</location>
</feature>
<feature type="strand" evidence="10">
<location>
<begin position="804"/>
<end position="806"/>
</location>
</feature>
<feature type="turn" evidence="11">
<location>
<begin position="808"/>
<end position="810"/>
</location>
</feature>
<feature type="turn" evidence="7">
<location>
<begin position="813"/>
<end position="815"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="817"/>
<end position="819"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="824"/>
<end position="827"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="831"/>
<end position="833"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="834"/>
<end position="842"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="844"/>
<end position="858"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="862"/>
<end position="870"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="876"/>
<end position="892"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="901"/>
<end position="905"/>
</location>
</feature>
<feature type="strand" evidence="9">
<location>
<begin position="907"/>
<end position="910"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="913"/>
<end position="917"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="924"/>
<end position="929"/>
</location>
</feature>
<feature type="turn" evidence="8">
<location>
<begin position="930"/>
<end position="933"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="934"/>
<end position="936"/>
</location>
</feature>
<feature type="turn" evidence="8">
<location>
<begin position="995"/>
<end position="998"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1002"/>
<end position="1021"/>
</location>
</feature>
<feature type="strand" evidence="10">
<location>
<begin position="1024"/>
<end position="1026"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1031"/>
<end position="1033"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1034"/>
<end position="1036"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1038"/>
<end position="1040"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1042"/>
<end position="1044"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1048"/>
<end position="1050"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="1053"/>
<end position="1055"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1059"/>
<end position="1062"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="1065"/>
<end position="1067"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1069"/>
<end position="1071"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1074"/>
<end position="1079"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1084"/>
<end position="1099"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="1105"/>
<end position="1108"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1113"/>
<end position="1121"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1133"/>
<end position="1142"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1147"/>
<end position="1149"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="1153"/>
<end position="1167"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2M59"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2X1W"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2XIR"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3C7Q"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3KVQ"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3S35"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3VHE"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3VO3"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3WZD"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4AGC"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4ASE"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="21406692"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000250"/>
<evidence key="14" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P35918"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000255"/>
<evidence key="16" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00114"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10037737"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10102632"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10368301"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10590123"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10600473"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11387210"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11807987"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12649282"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12881528"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1417831"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15026417"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15215251"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15837294"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15962004"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1656371"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16959974"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16966330"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17004325"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17253678"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17303569"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18529047"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18593464"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18931684"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18936167"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19033661"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19136612"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19668192"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19834490"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20080685"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20145116"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20224550"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20705758"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21827946"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21893193"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23199280"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23529610"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7929439"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9160888"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9804796"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9837777"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="18593464"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="19668192"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000305"/>
<sequence length="1356" mass="151527" checksum="59E7C44B05CFEBB3" modified="2000-12-01" version="2" precursor="true">
MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLD
WLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQD
YRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWD
SKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGE
KLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRS
DQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPP
EIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVP
PQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPY
PCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGE
RVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPT
PVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLT
VLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNR
NLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWL
LLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPL
GRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVN
LLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLK
RRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLA
SRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDR
VYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTML
DCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVS
CMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDS
GMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYS
SEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>